Exicure Stock Rockets 70% on Clinical Trials, BlackRock Still In

Jakarta, Gotrade News - Exicure just recorded some serious gains in the market. This massive jump happened right after the company dropped some big news about their latest biotech breakthrough.

Keytakeaways:

• Exicure stock jumped 70% to hit $9 thanks to positive Phase 2 clinical results for burixafor.
• The therapy achieved a 90% success rate in trial participants within a short time.
• Institutional giants like BlackRock and Carlyle Group are still maintaining their positions in this stock.

Trading under the ticker XCUR, the stock surged 70% during pre-market trading on December 9, 2025. The price hit $9 after taking a steep nosedive for most of the year.

The Main Catalyst

The price spike was fueled by positive results from Phase 2 clinical trials for a drug called burixafor. Basically, this drug helps mobilize stem cells for patients getting ready for transplants.

According to a report from Finbold, nearly 90% of trial participants hit the required cell thresholds. The therapy even remained effective for patients who had a tough time with previous treatments.

Backing from the Giants

This price jump also shines a spotlight on the big money behind this biotech firm. It turns out, some heavy hitters in the investment world are still holding onto this stock.

Finbold noted that BlackRock, Inc. held 5,730 shares as of September 2025. Besides them, The Carlyle Group Inc. and Vanguard are also listed as institutional investors.

Referensi:

• Finbold, This BlackRock stock just rocketed 70%. Accessed on December 10, 2025
• Featured Image: Shutterstock

Disclaimer:

Gotrade is the trading name of Gotrade Securities Inc., registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.